Repligen (RGEN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on February 20. Analyst Puneet Souda from Leerink Partners maintained a Buy rating on the stock and has a $200.00 price target.
Puneet Souda’s rating is based on Repligen’s strong performance in key areas and positive growth indicators. The company reported solid revenue for the fourth quarter of 2024, reaching $167.5 million, which aligns with market expectations. Repligen’s core business, particularly with Contract Development and Manufacturing Organizations (CDMOs) and capital equipment, showed signs of recovery, with orders increasing by 11% quarter-over-quarter. This indicates a healthy demand for Repligen’s offerings, outpacing revenue growth by 6%.
Additionally, Repligen’s optimistic guidance for fiscal year 2025 projects a 10-14% growth in its base business, surpassing market consensus. The company’s management highlighted robust demand in filtration, process analytics, and CDMO, with significant sequential increases in orders and sales. Despite minor headwinds from foreign exchange rates, the company’s gross and operating margins remain in line with expectations, contributing to the anticipated earnings per share range. This combination of factors supports the Buy rating as Repligen demonstrates resilience and potential for continued growth.
In another report released on February 21, KeyBanc also maintained a Buy rating on the stock with a $220.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com